Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli (FOREST)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02142751 |
|
Recruitment Status :
Completed
First Posted : May 20, 2014
Last Update Posted : August 6, 2019
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Enterobacterieaceae (and specially Escherichia coli) showing resistance due to multidrug-resistant Escherichia coli, plasmid mediated AmpC or quinolone resistance caused by chromosomal mechanisms have spread worldwide during the last decades. This is important because many of these isolates are also resistant to other first-line agents such as fluoroquinolones or aminoglycosides, leaving few available options for therapy, and this condition is associated with increased morbidity- mortality and length of hospital stay. While carbapenems are considered the drugs of choice for multidrug-resistant Escherichia coli and AmpC producers, recent data suggests that certain alternatives may be suitable for some types of infections.
At the present time, finding therapeutic alternatives to carbapenems and cephalosporins for the treatment of invasive infections due to multidrug-resistant Escherichia coli is critical. Fosfomycin was discovered more than 40 years ago but was not investigated according to present standards, and thus is not used in clinical practice except in desperate situations. It is one of the so-considered neglected antibiotics with high potential interest for the future.
With the aim of demonstrate the clinical non-inferiority of intravenous fosfomycin compared to meropenem or ceftriaxone in the treatment of bacteraemic urinary tract infections caused by multidrug-resistant Escherichia coli . The investigators propose a "real practise" randomised, controlled, multicentre phase III clinical trial to compare the clinical and microbiological efficacy and safety of intravenous fosfomycin (4 grammes every 6 hours) with meropenem (1 gramme every 8 hours) or ceftriaxone (1 gramme every 24 hours) as targeted therapy of the previously specified infection; change to oral therapy according to predefined options is allowed in both arms after 5 days. Follow-up for the study is planned up to 60 days.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Infection Due to ESBL Escherichia Coli | Drug: Fosfomycin sodium intravenous Drug: Meropenem intravenous Drug: Ceftriaxone intravenous | Phase 3 |
The FOREST study is a phase 3, randomised, controlled, multicentric, open-label clinical trial to prove the noninferiority of fosfomycin versus meropenem in the targeted treatment of bacteraemic UTI due to ESBL-EC, designed as a real practice trial. It is a non-commercial, investigator-driven clinical study funded through a public competitive call by Instituto de Salud Carlos III, Spanish Ministry of Economy (PI13/01282).
The study is coordinated by investigators from Hospital Universitario Virgen Macarena in Seville, Spain; the sponsorship is performed by Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI), of which the sponsor-scientific responsibilities are delegated to the CTU (Clinical Trial Unit-Hospital Universitario Virgen del Rocío, Seville, Spain). All participating patients or their relatives must give written informed consent before any study procedures occur, including the withdrawal of biological samples for the study.
The hypothesis to test is that intravenous fosfomycin is not inferior to meropenem for the targeted treatment of bacteraemic UTI caused by ESBL-EC in terms of efficacy.
The primary objective of the study is to demonstrate that intravenous fosfomycin is not inferior to meropenem for reaching clinical and microbiological cure 5-7 days after the completion of treatment.
Secondary objectives include comparing the early clinical and microbiological response, 30-day mortality, hospital stay, recurrence rate, safety and impact on intestinal colonisation by MDR Gram-negative bacilli, evaluation of the rate of resistance development to fosfomycin and blood level concentration of fosfomycin.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 161 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem or Ceftriaxone in the Treatment of Bacteriemic Urinary Infection Due to Multidrug Resistance in E.Coli |
| Actual Study Start Date : | July 2014 |
| Actual Primary Completion Date : | December 2018 |
| Actual Study Completion Date : | March 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Fosfomycin sodium intravenous
4g every 6 hours iv (60 min infusion)
|
Drug: Fosfomycin sodium intravenous
4g every 6 hours iv (60 min infusion)
Other Names:
|
|
Active Comparator: Meropenem intravenous
1g every 8 hours (15-30 min infusion)
|
Drug: Meropenem intravenous
1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
Other Names:
|
|
Ceftriaxone intravenous
1g every 24h (2-4 min)
|
Drug: Ceftriaxone intravenous
1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
Other Names:
|
- Clinical and microbiological cure rate [ Time Frame: Day 5-7 after end of treatment (test of cure) ]
Clinical Cure: Complete resolution of infection symptoms (bacteremia and/or urinary tract infection-UTI-), present at the day on which blood culture was drawn.
Microbiological cure: Negative blood culture at day 5-7 after end of treatment. Besides this, if UTI was confirmed with a positive urine culture with the same microorganism than the blood culture, this culture should become negative.
- Early clinical response [ Time Frame: After 5 -7 days of complete treatment (from the first day of study drugs administration) ]The infection was completely resolved after 5-7 days of complete treatment
- Mortality [ Time Frame: At day 30 of follow-up ]Death for any reason.
- Length of hospital stay [ Time Frame: At day 30 of follow-up ]It is defined as the time from admission to hospital discharge
- Safety of intravenous fosfomycin in this indication [ Time Frame: To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration) ]Gathering any related adverse event from the informed consent form signature to the end of follow-up.
- Recurrences (relapse and reinfection) rate [ Time Frame: To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration) ]
Relapse: new symptoms of UTI in patient with previously considered as clinical or microbiological cured in the visit of day 5-7 plus positive urine or blood cultures with the same microorganism isolated than the initial culture.
Re-infection: same definition but with different strain in the culture results.
- Fosfomycin steady-state plasma concentration [ Time Frame: At 3 days after treatment started ]Therapeutic drug monitoring of fosfomycin, basic pharmacokinetic parameters will be determined.
- Microbiota impact of study treatment bacilli [ Time Frame: Screening, day 5-7, day 12 ]Study treatment impact in the gut colonization of MDRGNB (Multi drug resistant Gram negative bacilli)
- Emergence of resistant clinical isolates of Escherichia coli to fosfomycin and meropenem [ Time Frame: participants will be followed for the duration of fosfomycin, an expected average of 14 days ]Frequency of strains that develop resistance and detection of resistance mechanisms in fosfomycin treatment arm.
- Early microbiological response [ Time Frame: within the first 5 days after treatment started ]Cultures are negative
- Safety of intravenous antibiotic administration in this indication [ Time Frame: To the last visit, at 60 plus-minus 10 days (from the first day of study drugs administration) ]Gathering any related adverse event from the informed consent form signature to the end of follow-up.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ≥18 years old hospitalized patients
- Negative pregnancy test in fertile women
- Episode of clinically-significant monomicrobial urinary BSI due to multidrug-resistant E.coli susceptible to fosfomycin and meropenem or ceftriaxone
- Urinary sepsis with multidrug resistant E. coli isolation from the blood cultures, requires at least one clinical criteria and one of the following urinalysis criteria:
Clinical criteria
- UTI symptoms (dysuriac, urgency, suprapubic pain or pollakiuria)
- Lumbar back pain
- Cost-vertebral angle tenderness
- Altered mental status in people up to 70 years old
- Intermittent or permanent indwelling foley catheter (or withdrawal during 24 hours previous) even without urinary symptoms urinalysis criteria
- Urine dipstick test positive for either nitrites or leukocyte esterase
- Positive urine culture - Signed informed consent form (ICF) executed prior to protocol screening assessments
Exclusion Criteria:
- Polymicrobial bacteremia
- No drainage of renal abscess or obstructive uropathy unresolved
- Pregnant or careening women
- Haematogenous infection
- Other concomitant infection
- Renal transplantation recipients
- Polycystic kidney
- Hypersensitivity and/or intolerance to meropenem or fosfomycin or ceftriaxone
- Palliative care or life expectance < 90 days
- Septic shock at time of randomization
- New York Heart Association (NYHA) functional Class IV, hepatic cirrhosis or renal impairment receiving dialysis
- Active empiric treatment >72 hours
- Late randomization >24 hours after multidrug resistant.coli blood culture´s identification
- Participation in other clinical trial with active treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02142751
Show 22 study locations
| Study Chair: | JESUS RODRIGUEZ-BAÑO, MD, PhD | Spanish Network for Research in Infectious Diseases |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| ClinicalTrials.gov Identifier: | NCT02142751 |
| Other Study ID Numbers: |
FOREST |
| First Posted: | May 20, 2014 Key Record Dates |
| Last Update Posted: | August 6, 2019 |
| Last Verified: | August 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
Fosfomycin Escherichia coli Extended-spectrum β-lactamases (ESBLs) Bacteremia Urinary tract infection Bloodstream infection |
Meropenem Pharmacokinetics intestinal colonization Recurrence multidrug resistance E.coli Ceftriaxone |
|
Fosfomycin Infections Communicable Diseases Escherichia coli Infections Disease Attributes Pathologic Processes Enterobacteriaceae Infections Gram-Negative Bacterial Infections |
Bacterial Infections Bacterial Infections and Mycoses Meropenem Ceftriaxone Pharmaceutical Solutions Anti-Bacterial Agents Anti-Infective Agents |